Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis

Authors

Jerome De Seze (ORCID: https://orcid.org/0000-0002-7197-7578)
Min Wu (ORCID: https://orcid.org/0000-0001-5490-3916)
Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
Jin Nakahara (ORCID: https://orcid.org/0000-0002-5858-0998)
David Paling (ORCID: https://orcid.org/0000-0003-4577-1821)
Gabriel Pardo (ORCID: https://orcid.org/0000-0002-2207-3708)
Roseanne Sullivan (ORCID: https://orcid.org/0000-0001-6025-465X)
Jun Li (ORCID: https://orcid.org/0000-0001-7541-752X)
Heinz Wiendl (ORCID: https://orcid.org/0000-0001-5509-1075)
Stephen L. Hauser (ORCID: https://orcid.org/0000-0002-4932-4001)
Mark S. Freedman
Anil Abeyewickreme

Institutions

Novartis (Switzerland) (CH)
University of California, San Francisco (US)
Keio University (JP)
Ottawa Hospital (CA)
University Medical Center Freiburg (DE)
Royal Hallamshire Hospital (GB)
Oklahoma Medical Research Foundation (US)
Vall d'Hebron Hospital Universitari (ES)
Novartis (United Kingdom) (GB)
Klinik und Poliklinik für Neurologie (DE)
Université de Strasbourg (FR)

Publication Details

Journal: Multiple Sclerosis and Related Disorders
Published: 2025-11-25
DOI: https://doi.org/10.1016/j.msard.2025.106886
Primary Topic: Multiple Sclerosis Research Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis

Jerome De Seze, Min Wu, Xavier Montalbán, Jin Nakahara et al.

Nov 25, 2025

Multiple Sclerosis and Related Disorders

Multiple Sclerosis Research Studies

article

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis

Jerome De Seze, Min Wu, Xavier Montalbán, Jin Nakahara, David Paling, Gabriel Pardo, Roseanne Sullivan, Jun Li, Heinz Wiendl, Stephen L. Hauser, Mark S. Freedman, Anil Abeyewickreme

November 25, 2025article en

Abstract

No abstract available for this paper.

Multiple Sclerosis and Related DisordersVol. 105

Novartis (Switzerland) (CH), University of California, San Francisco (US), Keio University (JP), Ottawa Hospital (CA), University Medical Center Freiburg (DE), Royal Hallamshire Hospital (GB), Oklahoma Medical Research Foundation (US), Vall d'Hebron Hospital Universitari (ES), Novartis (United Kingdom) (GB), Klinik und Poliklinik für Neurologie (DE), Université de Strasbourg (FR)

Openalex Percentile: Top 50%

Multiple Sclerosis Research Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis — Jerome De Seze, Min Wu, et al. · Multiple Sclerosis and Related Disorders (2025) | TGRS Research Map | TGRS